Pursuant to Regulation 30 & 33 of the SEBI (LODR) Regulations, 2015, please find enclosed herewith the following: 1. Unaudited Financial Results (Standalone & Consolidated) for the Quarter ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.3 pts more than Nifty Microcap 250 and 8.2 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shree Pacetronix Ltd, a cardiac pacing device (Life Saving Devices) maker, reported strong Q1 FY26 results. Revenue from operations rose to Rs. 534.30 lakhs from Rs. 485.42 lakhs in Q1 FY25, a growth of about 10%. Profit after tax jumped nearly 80% to Rs. 67.00 lakhs (standalone) from Rs. 37.24 lakhs a year ago. Basic EPS improved to Rs. 1.86 from Rs. 1.03. Consolidated PAT was Rs. 66.47 lakhs with revenue of Rs. 534.30 lakhs, and subsidiary Shree Coratomic Limited contributed negligible revenue (Rs. 1.21 lakhs) with a small loss. The auditor (S R Naredi & Co.) issued a clean limited review report with no qualifications on both standalone and consolidated results.
Sharp PAT growth driven by margin expansion is positive for shareholders and likely to be viewed favorably by the market, though revenue growth is modest. No red flags from the auditor — clean review and no exceptional items strengthen confidence in the print.